908 Devices' (MASS) Sell (E+) Rating Reaffirmed at Weiss Ratings

Weiss Ratings restated their sell (e+) rating on shares of 908 Devices (NASDAQ:MASS - Free Report) in a research report sent to investors on Saturday,Weiss Ratings reports.

Other analysts have also recently issued reports about the company. Leerink Partners reaffirmed a "market perform" rating and issued a $4.00 price target (down from $12.00) on shares of 908 Devices in a research note on Wednesday, November 13th. Stephens reaffirmed an "overweight" rating and issued a $6.00 price objective on shares of 908 Devices in a research report on Wednesday, January 15th. Leerink Partnrs lowered 908 Devices from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, November 13th. Finally, Stifel Nicolaus cut their price objective on shares of 908 Devices from $17.00 to $6.00 and set a "buy" rating on the stock in a research report on Wednesday, November 13th. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $5.33.

908 Devices Trading Down 7.5 %

Shares of NASDAQ:MASS traded down $0.19 during trading on Friday, hitting $2.36. 255,683 shares of the company's stock were exchanged, compared to its average volume of 969,491. The firm has a 50-day moving average price of $2.34 and a two-hundred day moving average price of $3.24. 908 Devices has a 1-year low of $1.81 and a 1-year high of $7.91. The firm has a market cap of $82.18 million, a P/E ratio of -1.33 and a beta of 0.98.

Institutional Investors Weigh In On 908 Devices

A number of institutional investors and hedge funds have recently modified their holdings of MASS. 49 Wealth Management LLC boosted its holdings in shares of 908 Devices by 16.2% during the 3rd quarter. 49 Wealth Management LLC now owns 31,099 shares of the company's stock worth $108,000 after buying an additional 4,343 shares during the period. State Street Corp grew its position in 908 Devices by 1.2% during the third quarter. State Street Corp now owns 479,044 shares of the company's stock worth $1,662,000 after buying an additional 5,704 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of 908 Devices by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 567,788 shares of the company's stock worth $1,970,000 after purchasing an additional 6,634 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of 908 Devices in the third quarter worth $36,000. Finally, B. Riley Wealth Advisors Inc. acquired a new position in shares of 908 Devices in the 3rd quarter valued at approximately $45,000. 88.06% of the stock is owned by institutional investors.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.